You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天津就生物医药产业高质量发展提10类支持政策
阿思达克 06-28 14:22

天津市市场监管委、天津市药监局、天津市知识产权局昨日(27日)召开「支持生物医药产业高质量发展改革措施」新闻发布会,发布《关於进一步支持我市生物医药产业高质量发展的若干意见》,提出10类支持政策。

该意见提出,积极承接北京非首都功能疏解,吸引创新型、龙头型、互补型医疗器械生产企业落户天津,对满足生产条件和产品安全性底线要求的,直接采信北京许可结论、直接发证,最大限度简化审评审批。

同时,将药品再注册事项审批时限由6个月压缩至15日,药品审评事项时限由40日压缩至20日,将药品检验事项办理时限由60日压缩至30日;将大力支持创新药生产企业落地生产,针对国家药品监管局直接受理和审批的新药,实施早期介入、全程跟踪等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account